Total Payments
$14,641
2024 Payments
$8,450
Companies
10
Transactions
41
Medicare Patients
159
Medicare Billing
$19,437
Payment Breakdown by Category
Consulting$6,375 (43.5%)
Travel$3,673 (25.1%)
Other$3,000 (20.5%)
Food & Beverage$1,566 (10.7%)
Education$27.27 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,375 | 3 | 43.5% |
| Travel and Lodging | $3,673 | 9 | 25.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 1 | 20.5% |
| Food and Beverage | $1,566 | 27 | 10.7% |
| Education | $27.27 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $14,039 | 28 | $0 (2024) |
| Axsome Therapeutics, Inc. | $124.84 | 1 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $96.37 | 1 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $85.92 | 1 | $0 (2021) |
| ABBVIE INC. | $71.46 | 2 | $0 (2023) |
| ITI, Inc. | $64.19 | 1 | $0 (2022) |
| Ironshore Pharmaceuticals Inc. | $50.00 | 3 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $47.20 | 1 | $0 (2023) |
| Lundbeck LLC | $35.50 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,450 | 13 | Neurocrine Biosciences, Inc. ($8,387) |
| 2023 | $304.01 | 5 | Axsome Therapeutics, Inc. ($124.84) |
| 2022 | $5,692 | 20 | Neurocrine Biosciences, Inc. ($5,577) |
| 2021 | $195.79 | 3 | Janssen Pharmaceuticals, Inc ($96.37) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $90.90 | General |
| Category: Neuropsychiatry | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 07/24/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.50 | General |
| Category: PSYCHIATRY | ||||||
| 05/16/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,812.50 | General |
| 05/16/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| 04/05/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $21.00 | General |
| 04/04/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $33.48 | General |
| 04/03/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $755.55 | General |
| 04/03/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $276.05 | General |
| 04/03/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $17.98 | General |
| 03/05/2024 | Neurocrine Biosciences, Inc. | — | Travel and Lodging | In-kind items and services | $817.20 | General |
| 01/11/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 10/19/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $57.96 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $58.85 | General |
| Category: Neuropsychiatry | ||||||
| 10/06/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Neuropsychiatry | ||||||
| 04/20/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | Cash or cash equivalent | $124.84 | General |
| Category: Psychology/Psychiatric | ||||||
| 03/30/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $47.20 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $32.33 | General |
| Category: Neuropsychiatry | ||||||
| 10/26/2022 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 10/20/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $64.19 | General |
| Category: PSYCHIATRY | ||||||
| 07/26/2022 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 07/19/2022 | Neurocrine BioSciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Neuropsychiatry | ||||||
| 06/17/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | Cash or cash equivalent | $277.84 | General |
| Category: Neuropsychiatry | ||||||
| 06/17/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Neuropsychiatry | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 28 | 77 | $17,248 | $5,223 |
| 2022 | 2 | 43 | 89 | $17,050 | $5,114 |
| 2021 | 2 | 42 | 106 | $18,712 | $5,427 |
| 2020 | 2 | 46 | 92 | $15,650 | $3,673 |
Total Patients
159
Total Services
364
Medicare Billing
$19,437
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 77 | $17,248 | $5,223 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 50 | $11,200 | $3,423 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 39 | $5,850 | $1,690 | 28.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 68 | $10,200 | $3,144 | 30.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 38 | $8,512 | $2,282 | 26.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 29 | 67 | $10,050 | $2,365 | 23.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 17 | 25 | $5,600 | $1,308 | 23.4% |
About Daniel Wesemann, LISW, ARNP
Daniel Wesemann, LISW, ARNP is a Clinical healthcare provider based in Davenport, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1366435125.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Daniel Wesemann, LISW, ARNP has received a total of $14,641 in payments from pharmaceutical and medical device companies, with $8,450 received in 2024. These payments were reported across 41 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($6,375).
As a Medicare-enrolled provider, Wesemann has provided services to 159 Medicare beneficiaries, totaling 364 services with total Medicare billing of $19,437. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical
- Other Specialties Clinical, Psychiatric/Mental Health
- Location Davenport, IA
- Active Since 08/26/2005
- Last Updated 04/21/2021
- Taxonomy Code 1041C0700X
- Entity Type Individual
- NPI Number 1366435125
Products in Payments
- INGREZZA (Drug) $5,045
- Ongentys (Drug) $139.80
- Auvelity (Drug) $124.84
- SPRAVATO (Drug) $96.37
- AUSTEDO (Drug) $85.92
- REXULTI (Drug) $82.70
- VRAYLAR (Drug) $71.46
- CAPLYTA (Drug) $64.19
- JORNAY PM (Drug) $50.00
- COBENFY (Drug) $27.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.